Biomunex CSO defines lead compounds, early R&D plans

April 11, 2017 Christoph Graener

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company’s bispecific antibody pipeline and how its candidates are different from other cancer therapies in development in this area. Zhukovsky outlines the company’s early development design and the timeline for its lead compounds, which are yet to enter the clinic, in solid and hematological cancers.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Eugene Zhukovsky – CSO, Biomunex

Previous Article
Prexton CEO on future for novel Parkinson’s therapy

Francois Conquet, CEO of Prexton Therapeutics, a biotech focused on central nervous system disorders, discu...

Next Article
Biomunex CEO on earlier deals for cancer drugs

Biomunex CEO Pierre-Emmanuel Gerard discusses the company's pipeline of innovative bispecific antibodies be...